Neoprobe changes name to Navidea
This article was originally published in Clinica
Dublin, Ohio-based radiotracer developer Neoprobe has changed its name to Navidea Biopharmaceuticals – a play on the words "navigating ideas". The company said it represents it dedication to "translate cutting edge innovation and precision diagnostics technology into novel products to advance patient care". Also this month, former president and CEO David Bupp retired from his role as director. The moves appear to be part of the firm's strategy of focusing on its lead products, the radiopharmaceutical agents Lymphoseek and RIGScan, which started in May when it sold off its line of gamma detection devices to Devicor Medical Products (www.clinica.co.uk, 26 May 2011).